Patient-Centric Medical Affairs: From High-Level Strategy to Day-to-Day Impact
Discover how top-down patient engagement transforms Medical Affairs—driving true patient-centricity, meaningful impact, and lasting success.
Discover how top-down patient engagement transforms Medical Affairs—driving true patient-centricity, meaningful impact, and lasting success.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
In this webinar, we will discuss the regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we discuss the benefits of taking an analytical approach.
This webinar aims to help viewers articulate why it’s important to consider a patient community audience when planning scientific and data dissemination including incorporating their voice within it.
MAPS speaks with Liz de Somer, CEO of Medicines Australia and Sharon Winton, CEO of Lymphoma Australia to explore patient engagement from the perspectives of industry and patient associations.
In this on-demand webinar, our experts provide guidance and potential solutions on addressing major barriers for patient centricity initiatives identified through their survey.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
This webinar serves as guidance for how to overcome barriers to access patients compliantly.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
